XORTX Therapeutics Inc. (XRTX) stock
Close on Nov 13, 2026Market cap $120.56KP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Dec 31, 2025
Valuation
- Market cap
- C$170.06K
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Diluted shares
- 5M
Trading
- Previous close
- $0.92
- Open
- $0.91
- Day's range
- $0.82 – $1.20
- Volume
- 1,595,983
- Average volume (20 days)
- 146,811
- Beta (5 years)
- 0.64
- RSI (14 days)
- 47.8
- Volatility (1 year)
- 102.5%
- Relative volume
- 3.03×
- WACC
- 8.3%
Market cap history
Month-end market cap since 2022, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | XRTX | S&P 500 | Difference | XRTX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -34.5% | -3.0% | −31.5 pts | ||
| 3 months | -49.8% | -2.8% | −47.0 pts | ||
| Year to date | -60.9% | +11.5% | −72.3 pts | ||
| 1 year | -60.7% | +13.5% | −74.1 pts | ||
| 3 years | -92.4% | +77.7% | −170.1 pts | -57.6% | +21.1% |
| 5 years | -99.9% | +72.6% | −172.5 pts | -74.9% | +11.5% |
| 10 years | -98.3% | +308.2% | −406.5 pts | -33.6% | +15.1% |
Eight years at a glance
Fiscal years 2018 to 2025, CAD
Press releases
Releases XORTX Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About XORTX Therapeutics
Pharmaceutical Preparations
XORTX Therapeutics Inc. is a clinical-stage biotechnology company focused on developing therapies for kidney disease and related conditions associated with aberrant purine metabolism and elevated uric acid. The company's lead programs utilize XORLO, an oral formulation of oxypurinol designed to inhibit xanthine oxidase. Key therapeutic programs include XRx-008 for autosomal dominant polycystic kidney disease and XRx-026 for individuals with gout who are intolerant to allopurinol. It has also explored precision medicine diagnostics and preclinical therapies targeting renal fibrosis. Its target patient populations and healthcare customers comprise individuals suffering from progressive renal disorders and gout.
Company profile, executives and historyXORTX Therapeutics stock: common questions
What is XORTX Therapeutics's stock price?
XRTX closed at $1.10 on Nov 13, 2026, up 19.57% on the day.
What is XORTX Therapeutics's market cap?
XORTX Therapeutics was worth $120.56K at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
Does XORTX Therapeutics pay a dividend?
No. XORTX Therapeutics has not paid a cash dividend over the last twelve months.
How has XRTX stock performed over the past year?
Including dividends, XRTX returned -60.7% over the past year, against +13.5% for the S&P 500.
Who are XORTX Therapeutics's competitors?
Companies most similar to XORTX Therapeutics by business, industry and size include UNCY, TVTX, EPRX, PHVS, AKBA.
See a number that looks wrong?